Horizon Discovery inks second cancer research deal with AstraZeneca
UK-based Horizon Discovery and Angl-Swedish drug major AstraZeneca (LSE: AZN) have entered into a research, collaboration and license agreement to explore a range of oncology-relevant genotypes with the aim of identifying and validating a number of novel drug targets.
This deal is the second research collaboration between the companies, the first being an oncology discovery program to explore Horizon’s first-in-class kinase target program, HD-001, worth clinical and approval milestones totaling up to $75 million, as well as tiered royalties (The Pharma Letter April 22, 2013).
Eligibility for $88 million in milestones
Under the terms of the latest accord, Horizon will receive an undisclosed upfront payment, and is eligible for subsequent payments of up to $88 million in milestones if compounds are developed by AstraZeneca against an undisclosed number of targets identified through the research collaboration.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze